Contact Us

These non-promotional scientific presentations were presented at the medical congresses referenced below and are intended for U.S healthcare professionals who were in attendance for the purposes of scientific exchange.

These materials may contain information outside of the FDA approved label or relate to uses that have not been approved by the FDA. Syndax does not recommend use of Syndax products in any manner other than as described in the FDA-approved Prescribing Information.

American Society of Hematology Annual Meeting 2025

Orlando, Florida Dec 6 - 9, 2025

Results 22

Oral Presentation | Dec 6, 2025

Revumenib for Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia: Outcomes by Leukemia Type in the Phase 2 AUGMENT-101 Study 1001

Aldoss I, et al.

View Material

Abstract | Dec 6, 2025

Pharmacodynamic Analysis of AGAVE-201 Indicates Changes in CSF-1R–Expressing Cells and Associated Biomarkers Potentially Contributing to Chronic Graft-Versus-Host Disease Resolution

Pratta MA, et al.

View Material

Abstract | Dec 6, 2025

Clinical and Disease Characteristics of Initial Participants at Time of Enrollment in THRIVE, a Prospective, Observational Cohort Study of Patients at Risk for Chronic Graft Versus Host Disease

Lee CJ, et al.

View Material

Abstract | Dec 6, 2025

CSF1R-CSF1 Axis Blockade with Axatilimab Effectively Targets Leukemia Stem Cells and Monocytes in AML Resistant to BH3 Mimetics

Carter BZ, et al.

View Material

Abstract | Dec 6, 2025

Safety Analysis of Axatilimab in Patients With Chronic Graft-Versus-Host Disease in an Expanded Access Program

Shune L, et al.

View Material

Abstract | Dec 6, 2025

Phase 1b/2 study of axatilimab in combination with azacitidine in advanced Phase MPN, MDS/ MPN overlap and high-risk CMML

Borate U, et al.

View Material

Abstract | Dec 6, 2025

Trial in Progress: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Moderate to Severe Chronic Graft-Versus-Host Disease

DeFilipp Z, et al.

View Material

Poster Presentation | Dec 6, 2025

Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: interim safety analysis of a phase 2, randomized study

Zeiser R, et al.

View Material

Abstract | Dec 6, 2025

Safety and Feasibility of 0.6 mg/kg Every 4 Weeks Dosing of Axatilimab in Patients Treated in the AGAVE-201 Study

Farhadfar N, et al.

View Material